Evidence map›Paper›PMID 24048854›Full record

ArticleThe Journal of neuroscience : the official journal of the Society for Neuroscience2013

Cyclooxygenase-1-dependent prostaglandins mediate susceptibility to systemic inflammation-induced acute cognitive dysfunction.

Éadaoin W Griffin, Donal T Skelly, Carol L Murray, Colm Cunningham

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of neuroscience : the official journal of the Society for Neuroscience, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed, 1 pooled it
8.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 1 synthesis or guideline pooled it, 102 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Neuroinflammation in Alzheimer disease.Nature reviews. Immunology · 2025
    Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Synthesis and Preclinical Evaluation ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022
    Article
  13. Article
  14. Article
  15. Review
  16. Is cyclooxygenase-1 involved in neuroinflammation?Journal of neuroscience research · 2021
    Review
  17. Article
  18. Article
  19. Article
  20. Pharmacological Screening ofFrontiers in pharmacology · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Éadaoin W GriffinTrinity College Institute of Neuroscience and School of Biochemistry and Immunology, Trinity College Dublin, Dublin, Republic of Ireland.
Donal T Skelly
Carol L Murray
Colm Cunningham
Trinity College Dublin · IE

Funding

Wellcome Trust 090907Wellcome Trust SRF 090907/Z/09/A
6 · The paper itself

Abstract

Systemic inflammatory events often precipitate acute cognitive dysfunction in elderly and demented populations. Delirium is a highly prevalent neuropsychiatric syndrome that is characterized by acute inattention and cognitive dysfunction, for which prior dementia is the major predisposing factor and systemic inflammation is a frequent trigger. Inflammatory mechanisms of delirium remain unclear. We have modeled aspects of delirium during dementia by exploiting progressive neurodegeneration in the ME7 mouse model of prion disease and by superimposing systemic inflammation induced by the bacterial endotoxin lipopolysaccharide (LPS). Here, we have used this model to demonstrate that the progression of underlying disease increases the incidence, severity, and duration of acute cognitive dysfunction. This increasing susceptibility is associated with increased CNS expression of cyclooxygenase (COX)-1 in microglia and perivascular macrophages. The COX-1-specific inhibitor SC-560 provided significant protection against LPS-induced cognitive deficits, and attenuated the disease-induced increase in hippocampal and thalamic prostaglandin E2, while the COX-2-specific inhibitor NS-398 was ineffective. SC-560 treatment did not alter levels of the proinflammatory cytokines interleukin (IL)-1β, tumor necrosis factor-α, IL-6, or C-X-C chemokine ligand 1 in blood or brain, but systemic IL-1RA blocked LPS-induced cognitive deficits, and systemic IL-1β was sufficient to induce similar deficits in the absence of LPS. Furthermore, the well tolerated COX inhibitor ibuprofen was protective against IL-1β-induced deficits. These data demonstrate that progressive microglial COX-1 expression and prostaglandin synthesis can underpin susceptibility to cognitive deficits, which can be triggered by systemic LPS-induced IL-1β. These data contribute to our understanding of how systemic inflammation and ongoing neurodegeneration interact to induce cognitive dysfunction and episodes of delirium.

Indexed as

Cognition DisordersAnalysis of VarianceAnimalsBrainCalcium-Binding ProteinsCyclooxygenase 1Cyclooxygenase 2CytokinesDisease Models, AnimalEnzyme InhibitorsFemaleGene Expression RegulationInflammationIntramolecular OxidoreductasesLipopolysaccharidesMaze LearningAif1 protein, mouseCalcium-Binding ProteinsCyclooxygenase 1Cyclooxygenase 2CytokinesEnzyme InhibitorsIntramolecular OxidoreductasesLipopolysaccharidesMicrofilament ProteinsProstaglandin-E SynthasesProstaglandinsPyrazolesRNA, MessengerSC 560

Identifiers

PMID24048854
PMCPMC3776067
OpenAlexW2008706479

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.